Skip to main content

Compass Therapeutics, Inc 8-K, filed Nov 9, 2026

Compass Therapeutics, Inc. (CMPX)

8-K 2026-11-09 For: 2026-11-09
View Original
Added on November 09, 2026

About this 8-K

Compass Therapeutics, Inc filed this 8-K on November 9, 2026.

Compass Therapeutics is preparing a tovecimig BLA for biliary tract cancer despite FDA's recommendation for an additional survival-benefit study. It reported a $27.2 million quarterly net loss, with $163 million in cash and marketable securities expected to fund operations into 2028. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits